Ipilumimab

Phase 2Monoclonal antibody

TThe Netherlands Cancer Institute

Ipilumimab is one of 3 small molecule programs targeting ARDS. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ARDSRecruiting

ARDSPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in ARDS

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

1 2

MRG-001

MMedRegen LLC

Phase 2

1 3

Ipilumimab

TThe Netherlands Cancer Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

ARDS

NCT06823479

Clinical

Trials by Indication[1]

ARDS1 trial

Towards Cure Via Only Ultra-short ICB in CSCC

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT06823479·41 enrolled

Melanoma1 trial

A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma

Completed·—·Phase 1·NCT01996202·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ipilumimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ipilumimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ipilumimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Netherlands Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: TThe Netherlands Cancer Institute

Ipilumimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

ARDS1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News